IL153907A0 - PHARMACEUTICAL COMPOSITIONS CONTAINING 2-METHYLENE-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3 - Google Patents

PHARMACEUTICAL COMPOSITIONS CONTAINING 2-METHYLENE-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3

Info

Publication number
IL153907A0
IL153907A0 IL15390701A IL15390701A IL153907A0 IL 153907 A0 IL153907 A0 IL 153907A0 IL 15390701 A IL15390701 A IL 15390701A IL 15390701 A IL15390701 A IL 15390701A IL 153907 A0 IL153907 A0 IL 153907A0
Authority
IL
Israel
Prior art keywords
1alpha
dihydroxyvitamin
methylene
pharmaceutical compositions
compositions containing
Prior art date
Application number
IL15390701A
Other languages
English (en)
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of IL153907A0 publication Critical patent/IL153907A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15390701A 2000-07-14 2001-07-10 PHARMACEUTICAL COMPOSITIONS CONTAINING 2-METHYLENE-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3 IL153907A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61616400A 2000-07-14 2000-07-14
PCT/US2001/021706 WO2002005823A2 (en) 2000-07-14 2001-07-10 USE OF 2-METHYLENE-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH

Publications (1)

Publication Number Publication Date
IL153907A0 true IL153907A0 (en) 2003-07-31

Family

ID=24468290

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15390701A IL153907A0 (en) 2000-07-14 2001-07-10 PHARMACEUTICAL COMPOSITIONS CONTAINING 2-METHYLENE-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3
IL153907A IL153907A (en) 2000-07-14 2003-01-13 Pharmaceutical preparations containing 2 - methylene – 19 – nur – (S) 20 –1α, 25– dihydroxyvitamin D3

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153907A IL153907A (en) 2000-07-14 2003-01-13 Pharmaceutical preparations containing 2 - methylene – 19 – nur – (S) 20 –1α, 25– dihydroxyvitamin D3

Country Status (13)

Country Link
US (3) US7115594B2 (xx)
EP (1) EP1301189A2 (xx)
JP (1) JP2004505022A (xx)
KR (1) KR100572957B1 (xx)
CN (1) CN1217664C (xx)
AU (2) AU7888801A (xx)
BR (1) BR0112454A (xx)
CA (1) CA2416194C (xx)
HK (1) HK1060304A1 (xx)
IL (2) IL153907A0 (xx)
MX (1) MXPA03000406A (xx)
NZ (1) NZ537036A (xx)
WO (1) WO2002005823A2 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
WO2004076468A1 (ja) 2003-02-25 2004-09-10 Kobe Tennenbutsu Kagaku Kabushiki Kaisha ビタミンｄ誘導体を合成するための新規な中間体
WO2005027919A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture
WO2005027920A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency
EP1667692A1 (en) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
WO2005027930A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. 2-alkylene-19-nor-vitamin d derivatives for the treatment of osteosarcoma
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7713951B2 (en) * 2004-04-09 2010-05-11 Wisconsin Alumni Research Foundation 2-alkylidene-18,19-dinor-vitamin D compounds
EP1812011A1 (en) 2004-11-12 2007-08-01 Bioxell S.p.a. Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
AU2005309791A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and its uses
WO2006061683A1 (en) * 2004-12-09 2006-06-15 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta
US8193169B2 (en) 2006-04-06 2012-06-05 Wisconsin Alumni Research Foundation (20R)-2α-methyl-19,26,2-trinor-vitamin D analogs
EP2021320A2 (en) 2006-04-06 2009-02-11 Wisconsin Alumni Research Foundation 2-substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin d analogs and uses thereof
US20110034426A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of Preventing Renal Disease and Treating Symptoms Thereof
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
JP5931845B2 (ja) * 2010-03-23 2016-06-08 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
JP5770261B2 (ja) * 2010-03-23 2015-08-26 ウイスコンシン アラムニ リサーチ ファンデーション （２０Ｓ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ジヒドロキシビタミンＤ３および（２０Ｒ）−２−メチレン−１９−ノル−２２−ジメチル−１α，２５−ヒドロキシビタミンＤ３
BR112014032847A2 (pt) * 2012-06-29 2017-06-27 Wisconsin Alumni Res Found uso de 2-metileno-19-nor-(20s)-1alfa,25-dihidroxivilamina d3 para o tratamento de hiperparatiroidismo secundário
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds

Also Published As

Publication number Publication date
CN1455672A (zh) 2003-11-12
KR20030016403A (ko) 2003-02-26
CN1217664C (zh) 2005-09-07
EP1301189A2 (en) 2003-04-16
JP2004505022A (ja) 2004-02-19
WO2002005823A2 (en) 2002-01-24
CA2416194C (en) 2009-10-06
NZ537036A (en) 2006-07-28
MXPA03000406A (es) 2003-06-06
KR100572957B1 (ko) 2006-04-24
WO2002005823A3 (en) 2002-05-23
IL153907A (en) 2009-08-03
AU7888801A (en) 2002-01-30
US20040068129A1 (en) 2004-04-08
AU2001278888B2 (en) 2005-04-07
HK1060304A1 (en) 2004-08-06
US7115594B2 (en) 2006-10-03
BR0112454A (pt) 2003-07-29
US20060135493A1 (en) 2006-06-22
US20060135492A1 (en) 2006-06-22
CA2416194A1 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
IL153907A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 2-METHYLENE-19-NOR-20(S)-1alpha, 25-DIHYDROXYVITAMIN D3
HK1036935A1 (en) Pharmaceutical compositions.
HUP0102483A3 (en) Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
MXPA03000771A (es) Nuevas composiciones farmaceuticas.
MXPA03007215A (es) Formulaciones farmaceuticas.
ZA200003121B (en) Flash-melt oral dose formulations.
HUP0301573A3 (en) Substituted arylpyrazines, pharmaceutical compositions containing them and their use
AU6219601A (en) Pharmaceutical compositions
HUP0104452A3 (en) Medicinal compositions, containing tricyclo compounds
MXPA03000387A (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina-1.
GB0009584D0 (en) Pharmaceutical compositions
HUP0400967A3 (en) Substituted 2-anilino-benzimidazoles, their use and pharmaceutical compositions containing them
ZA200210359B (en) Pharmaceutical compositions.
MXPA03002105A (es) Composiciones farmaceuticas.
MXPA03000837A (es) Composicion farmaceutica que contiene citalopram.
GB0008485D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
MXPA03005965A (es) Composicion farmaceutica que contiene citalopram.
IL139766A0 (en) Pharmaceutical compositions containing d-chiro-inositol
ZA200110500B (en) Pharmaceutical composition.
HUP0204117A3 (en) Novel vitamin d analogues, pharmaceutical compositions containing them and their use
IL162880A0 (en) Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyk) dodecanoic acid
MXPA03007318A (es) Composicion farmaceutica.
AU8254101A (en) Medicinal compositions
ZA200110501B (en) Pharmaceutical composition.